Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lack of filing urgency is alarming.....
JonesBur...results timetable, filing delinquency.....
VODG(.175)...possible R&D development.....
Picked up a few more shares a couple of weeks ago for a possible trading pop/spike soon (see link below). This 20-cent area continues to look interesting to me as we wait for the FY 2018 press release. Just have a hunch/feeling there is going to be a pretty big tradeable move in the share price shortly after that PR is issued.
By the way, the stock I mentioned at the end of the below post is now trading at a fully-diluted valuation of $656M (7.29B shares x 9 cents/shr).....
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145931810
One thing I definitely want to see in this press release is a detailed/positive update and commentary on the filing delinquency situation. I know this sounds like a broken record, but I can't stress enough how important this is. I'm sure I am not the only investor who will be making adjustments to my position size in the first half of 2019 if management doesn't convey a sense of urgency regarding the filing delinquency.
Here is one thing that could turn into an interesting catalyst: It is possible (and I stress the word "possible") that VODG is currently modifying its stem cells for use in spinal fluid. The husband of one of the Vitro Biopharma patients in New Zealand made an update post on January 7 (2 weeks ago) regarding some future developments in her treatment for 2019.
He does not mention if these new stem cells will be coming from VODG or if another company is involved. If it turns out that these new cells are in fact coming from Vitro Biopharma, things could get extremely interesting here........
BESE(.0065)...management change on NVSOS.....
VBVT(.07)...shell debt acquired by Firetainment officer.....
VODG(.208)...expecting FY 2018 results soon.....
Extremely high-risk investment because of the filing delinquency. Having said that, I picked up some more shares at .205 last week for possible trading opportunities in the near future.
I'm semi-expecting to see the company release a FY 2018 press release soon (perhaps this week). I think there is a reasonably decent chance of seeing increased interest/volume in the stock during 2019 and maybe some nice tradeable moves in the share price.
VODG should be entering/continuing a period of growth in the stem cell therapy part of its business. The sales director that the company recently hired looks impressive and should be helpful in the marketing of all products/facets of the business. VODG registered its facility with the FDA for manufacturing/packaging of cosmetic products in mid-December, so it looks like the upcoming cosmetic product is on schedule for introduction in 2019. The CEO recently started updating his personal/business social media presence after about 3 years of silence.
Somewhat interesting to note in light of the recent reverse merger between AVOZ and Nurish.me LLC (which has a cognitive/immune supplement line): VODG has a cognitive/immune supplement line called NutraVivo. My hunch is that the company (and the new sales director) will probably try to increase market awareness of this product this year. Although it is not fair to compare VODG to AVOZ (which has a more established market presence) in this particular product area, it is interesting to note that AVOZ is currently trading at a fully-diluted market cap around $300M.
RNGC(.0048)...accumulated a position.....
Finished accumulating a good-sized position in the RNGC shell over the last couple of trading days. Extremely high-risk investment because of the filing delinquency, but hopefully the new management will move quickly to resolve that issue following the late December reinstatement.
This .004-.0051 price area looks reasonably attractive to me for entry/accumulation. The company/shell looked relatively clean (debt, overall share structure, etc.) around the time of its last quarterly filings (2013), so with some luck there could be some decent upside here.
https://www.nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=QQUBGr6sW3piylHhN4TLYA%253d%253d&nt7=0
BESE(.01)...added to my position.....
VODG(.22)...next 4 months should be interesting......
The next 4 months for VODG could turn out to be pretty interesting. Assuming the company maintains its schedule for financial performance press releases, we should be seeing at least two PRs in that time frame (FY 2018 and Q1 2019).
Given how informative its PRs have become, each of those press releases could be catalysts for tradeable spikes in the share price or sustained moves into higher trading ranges.
FY 2018 revenue should be well over $500k, and the quarter-over-quarter comparisons in early 2019 should look favorable. VODG has come a long way from the days when a $5-10K quarter was considered good.
I think it is a good idea to go back and read that Q3 press release again (see post above). VODG is telegraphing that business operations (on a number of fronts) are about to ramp up significantly in this coming year. That information regarding IRB-activity in foreign countries is potentially huge, especially when you consider how VODG's revenue to date has been positively influenced by exposure to basically just two clinics (New Zealand, Cayman Island).
https://vitrobiopharma.com/vitro-biopharma-3rd-quarter-ended-july-31st-2018-financial-results-of-operations/
m0n...BESE share structure......
BESE(.0081)...RM activity should be relatively close......
ECGI(.0038)...new CEO on NVSOS......
It has gone largely unnoticed, but it is somewhat interesting to note that ECGI changed its Registered Agent and filed its annual list on November 14. A new Ceo is now in charge (Donald Bell replaces Gary Blom).....
https://www.nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=kYOmkJYc62w2Hlxv%252fXZGzw%253d%253d
ECGI is easily the most frustrating/irritating investment I have ever made. The company was developing an ambulatory cardiac monitoring device called NowCardio (which has now been rebranded as "Liba3"). When one of the previous management/legal teams decided to acquire another product/technology (breast cancer detection area), the agreement they signed needlessly exposed ECGI to a large financial risk and this likely ended up being the ultimate downfall for the company. The management/legal team could have protected the company with just a simple sentence/paragraph/clause in the agreement, and none of the ensuing problems would have occurred.
This is the technology/product that would still be under the ECGI umbrella if it were not for that ill-advised agreement......
https://nationalcardiac.com/
Adding to the frustration from a retail shareholder perspective: To the best of my knowledge neither of the previous two CEOs (John Bentivoglio and Gary Blom) have ever provided any explanation/update as what exactly happened to the company and the current status of ECGI. Shareholders were left completely in the dark. So I am working under the assumption that ECGI is probably a shell at this point, and quite possibly a relatively "messy" looking shell for a number/variety of reasons.
The timing of the change in CEO is rather interesting. The two previous CEOs (and the company) appear to still be involved in some type of legal dispute.....
https://www.pacermonitor.com/public/case/23865032/Bentivoglio_et_al_v_Event_Cardio_Group_Inc_et_al
tjvs...revenue, May Kok......
tjvs...split, Focus Point....
BLLZ(.0055)...management change on NVSOS.....
Picked up another nice 100K block of shares on Tuesday at .005, in anticipation of seeing a management change reflected in the NVSOS annual list due on 10/31/2018.
It's very encouraging to see the filing was made on time, and BLLZ is now officially under different management. Still crossing my fingers and hoping things will look good from a structural standpoint. But even in situations where the structure/marketcap may not be ideal, sometimes these Asian reverse mergers can undergo some pretty wild/crazy/explosive moves in share price.
Based on the limited information in the July press release on the BLLZ website, I am assuming the new company/business is modeled to a large extent after Focus Point, which is the leading optical company in Malaysia.....
https://www.focus-point.com/about-us/
http://focuspoint.listedcompany.com/misc/ar2017.pdf
NVSOS management change.....
https://www.nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=neHhP9zJ7Wpkug6Gv1ksZg%253d%253d&nt7=0
CAPV(.003)...picked up a position.....
Keith Burge...Sales/Marketing Director for VODG......
The addition of Keith Burge as the Sales/Marketing Director is another good sign that business operations should be ramping up significantly in the upcoming year(s). Burge would also be an extremely interesting option for a future VODG CEO if Jim Musick ever decided to step aside.
Burge's most recent company that he co-founded is Confadent (dental gum product/tech). You can see him in this segment of Modern Living with kathy ireland......
https://confadent.com/blogs/news/modern-living-with-kathy-ireland
Keith Burge background information.....
https://www.bencolorado.org/keith-burge/
VODG October 23 press release......
Q3 press release...very encouraging.....
The Q3 2018 press release was extremely interesting. All indications suggest that VODG has finally turned the corner, with business activities ramping nicely, and potentially very interesting developments coming.
One thing I had hoped to see in this press release is management (either CEO Musick or CFO Evans) provide more information on the status of the filing delinquency. I can't stress enough how important it is for VODG to provide more transparency regarding this issue (see post above, for my concerns). The SEC seems to be getting more aggressive in its suspension/revocation activity (albeit, still inconsistent) in the last year. That continued threat to the stock has obvious influence/implications on the stock price and the safety of retail shareholder positions in this stock. Hopefully management will be very proactive in rectifying the delinquency, or at a minimum provide shareholders with a more detailed view of the situation.
Other than that, this press release was very encouraging. Some of the more interesting statements/comments in the PR centered around the guidance of being cashflow positive going forward, the cosmetic product, and IRBs that are currently under review in other countries......
Cashflow/Revenues: The statements/comments in the financial results section of the press release suggest/imply that VODG will probably be seeing $200+K revenue quarters going forward......
MAVT(.01)...Nevada filings updated.....
I picked up more shares this week (and over the last few months) to add to my position. SEC filings have been brought current. Nevada filings were updated over the last week (reflecting the management change, reverse split, and name change to "Viabuilt Ventures"). So it appears that everything is pretty much a "go" on this reverse merger getting completed and corporate activity should be increasing over the next few weeks/months.
https://www.nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=PJ3xL3WEx0vDBIBtVdqldg%253d%253d&nt7=0
Last quarterly report mentioned that a private placement is expected to occur with the merger. I continue to believe this price area looks extremely attractive for entry/accumulation, depending on some of the factors I mentioned in the post below......
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141652298
zjaye21...IBGH/QUBT, PLFM, Nutripy......
Hammer's statement appears on DVC website......
20-cent entry/accumulation area looks interesting......
I added a small amount recently in the low .20s for a possible short-term trading opportunity. IMO, the chances of seeing at least one nice pop/spike in the share price over the next month or two look pretty decent.
The last three press releases disclosing VODG's periodic earnings results have been issued around 2 months after the close of the fiscal quarter/year. Which means we should see the Q3 PR in roughly 3-4 weeks. In the absence of quarterly/annual filings, VODG seems to have taken the approach of making its press releases much more informative (more lengthy management commentary, interesting tidbits of information regarding its research/development, etc.). So every time you see a VODG press release hit the wires, there is a chance of seeing something that might cause a significant move in the share price.
If VODG has increased its financing placements to 20 cents (as per this Yahoo message board post a couple of weeks ago), that would seem to be a pretty good sign that we will be seeing higher prices down the road......
Life Sciences Biopharma...Louis Cona...cannaceuticals......
Interesting to note that Louis Cona (Medical Director of DVC Stem) is also the Chief Medical Officer of a relatively new company involved in the medicinal cannabis industry.
In the partners section of the DVC Stem website, you will notice that among the companies/organizations that DVC Stem is working with is a company called "Life Sciences Biopharma". The website for that company doesn't currently show much information beyond management and contact info, but you can find a very brief business description of the company here......
Michael Armand Hammer...possible endorsement of DVC Stem......
It probably wasn't noticed by very many people, but this morning DVC Stem posted on its Facebook page an endorsement by a very well-known businessman/philanthropist -- Michael Armand Hammer. It only appeared for less than an hour or so before the company apparently removed it.
From what I recall from the text of Hammer's statement, he had done research on various stem cell therapy clinics and ultimately chose DVC Stem for his stem cell treatment (which he received this year). According to Hammer his primary doctor(s) was pleased with the results, and Hammer recommended DVC Stem's services for anyone choosing that particular treatment route.
I'm not sure why DVC removed its post (maybe they posted it prematurely?), but it definitely was there this morning for at least 45 minutes to an hour.
https://en.wikipedia.org/wiki/Michael_Armand_Hammer
https://www.facebook.com/DVCStem/
George Sharp's involvement with EMPM......
One thing I would like to see George do is provide more clarification on exactly what his involvement with EMPM entails. For example, I would be curious to know if Sharp/EMPM have some sort of "official" agreement in place, whether EMPM is relying primarily or exclusively on Sharp to find and/or approve a RM candidate, and the nature/amount of any finder's fee that Sharp will receive.
EAD Law Group is EMPM's registered agent on its Nevada reinstatement filing (and perhaps EMPM's security counsel?). Ever since the EMPM reinstatement appeared (and before Sharp mentioned he had offered his services to the company), I have been assuming/guessing that EAD Law would be heavily involved in suggesting/picking a RM target for the EMPM shell. I figured the most likely RM target would probably be one of the many private companies that EAD Law Group has registered in Nevada during the last couple of years.
Some of those companies may go public through a direct registration process, but many will probably be future reverse merger candidates......
https://www.nvsos.gov/SOSEntitySearch/RACorps.aspx?fsnain=X81g5it%252bd1eRO42UpS7L%252bA%253d%253d&RAName=EAD+LAW+GROUP%2c+LLC
https://www.nvsos.gov/SOSEntitySearch/RACorps.aspx?fsnain=qLzmny0okzqfX%252bWqTcV%252bmw%253d%253d&RAName=EAD+LAW+GROUP%2c+LLC
BESE(.0032)...established a position.....
LWLW(2.00)...took a position in this shell.....
BLLZ(.025)...increased my position.....
Picked up a bunch more shares at 2 cents this morning, based on the apparent reverse merger that is taking place here. The June 17 press release on the BLLZ website went largely unnoticed, so I figured it might be a good idea to increase my position before the new CEO/company releases any official press release or makes a filing.
Definitely high-risk without knowing for sure what the final share structure will look like, or the financials of the RM target. But the BLLZ-related debt is being completely eliminated along with divesting the current business/operations. Since the Welch's control 90+% of the shares, the most ideal scenario here would be if the Welch family sold most (if not all) of their shares to the incoming RM company. I'm hoping and crossing my fingers that is what has happened here. That would leave a reasonably attractive share structure and leave potentially nice upside for the retail shareholders. Should be interesting to see how this plays out.
Some items of interest.....
1) Website: VODG's website has been offline for about 6-7 days. According to the company's Facebook page, the company is working on improving the e-commerce features of the site. I'm curious to see if there are any additional changes/upgrades to the site.
https://www.facebook.com/vitrodiaginc/
2) Fisher Scientific: When the website comes back online, it will be interesting to see if Fisher Scientific is still listed as a distributor of VODG products. Fisher first showed up in the "strategic partners" section of the website at the end of 2017 or very early 2018. But as far as I can recall, management has never made any public acknowledgement of that in any press release or filing. Having Fisher Scientific as a distributor is pretty big news, especially when you consider that VODG has relied primarily on in-house sales or just a couple/few small distributors over the years.
This is a cached page of VODG's website.....
https://webcache.googleusercontent.com/search?q=cache:gcD0iy4VVWoJ:https://vitrobiopharma.com/home/about/strategic-partners/+&cd=1&hl=en&ct=clnk&gl=us
3) The June 26 press release: Aside from the interesting information regarding the financial performance and financing-related activities, one thing that caused my eyebrow to raise a little bit with curiousity is that sentence in the "research and development" section of the PR.....
VODG...reply to private message....
To the person who sent me a private message regarding VODG......
I had posted on this board in June (if I recall correctly) but IHUB deleted the post shortly after it appeared, so I didn't bother to try again.
I still have my position, but it is admittedly difficult to continue holding the shares because the suspension/revocation risk might be increasing as every day goes by. Unfortunately, the company has put the retail shareholders in pretty much of a bind here with its public acknowledgement in the December 20, 2017 press release that it does not intend to maintain its reporting compliance.....
MRDH(.01)...subsidiary name change, wildcards, etc......
I continue to hold a large position in MRDH. High-risk investment without a doubt, but the "unusual" activity involving this stock/company (and its sister stock -- ICCO) over the last year or so continues to attract my attention. I don't know what is (or perhaps will be) occurring, but "something" certainly appears to be going on.
That activity, plus the potential wildcards of CEO Anthony Dike's still-active licensing agreements for NASA-related technologies, has me still holding tight to this position.
Some noteworthy things that have occurred over the last year.......
1) Anthony Dike filed a name change (MaxiCare Holdings Corporation) and address change with the Colorado SOS.
https://www.sos.state.co.us/biz/BusinessEntityHistory.do?&cmd=passgo&sc1=2
2) In mid-2017, Anthony Dike registered websites for MaxiCare and Vasocor (which is a medical device owned by ICCO).
3) ICCO had its OTC profile updated in January 2018. Although MRDH's profile page doesn't officially reflect it, I'm pretty sure its corporate address was updated on its OTC profile page around the same time.
4) MRDH has had a subsidiary called "Meridian Energy Corporation" registered in Colorado since 2005. In June 2018, Anthony Dike changed the name of that company to "SpectraCare Holdings Corporation".
https://www.sos.state.co.us/biz/BusinessEntityHistory.do?&cmd=passgo&sc1=2
Regarding the potential wildcards: Over the years Anthony Dike has entered into licenses/agreements to develop/commercialize NASA-related technologies. He usually does this through his private medical device research/development company (Meridian Health Systems, P.C.). One thing that has always intrigued me a little bit about MRDH/ICCO over the last few years is the possibility (perhaps remote) that Dike might use MRDH/ICCO to help commercialize any new devices/technologies from his private firm.
I've been monitoring the list of active Space Act Agreements that NASA puts out. As of the latest report (March 31, 2018), Meridian Health has two active agreements still in place. Both of them are set to expire in March 2019....
1) Annex 03 to MERIDIAN HEALTH SYSTEMS FOR
MICROWAVE TISSUE SOLDERING FOR WOUND
CLOSURE
2) Microwave Applications For Healthcare Treatments and
Radio Frequency Identification (RFID) Monitoring and
Tracking
https://www.nasa.gov/sites/default/files/atoms/files/active_domestic_nonfed_saas_house_approprs_action_as_of_3-31-2018.pdf
Given the pretty explosive share price movement that MRDH has shown in the past, if any of the wildcard plays came into play here, I think the market reaction would probably be quite interesting.
EMPM...my primary concern about the filing(s)......
I'm not 100% sure about this, but I think EMPM has made a mistake with its filings. And because of the amount of time that EMPM has been delinquent on its filings, they better get this corrected quickly.
I'm pretty sure that EMPM needed to file a Form 15-12G (to suspend its SEC filing obligations) before it filed the Form 10-12G.
If I am correct on this, I am a little surprised that this type of mistake would have been made since it appears that the company has some fairly competent people/entities working with it.
Based on the identity of the registered agent on the Nevada reinstatement, I am assuming that EAD Law Group is probably also acting as the securities counsel for EMPM. I don't know whether George Sharp has provided any advice/counsel on the filings or is just assisting with vetting reverse merger candidates.
EMPM(.006)...accumulated a position......
Accumulated a large position in the EMPM shell (or quasi-shell) last week. Extremely high-risk investment because of the filing delinquency and the overall valuation (market cap plus possible debt) of the shell is higher than I would prefer.
But if the company follows up its recent reinstatement with some filings, there could be some pretty decent upside from around this half-penny price level.
Somewhat interesting to note that the registered agent which handled EMPM's reinstatement (EAD Law Group) has registered more than 25 private companies in the last two years in the state of Nevada. That includes 7 just recently here in calendar 2018.
I haven't seen any speculation yet on what company/asset might be vended into the EMPM shell, but it wouldn't be surprising if it comes from that list of EAD-related Nevada companies. Some of those companies look like they could make for some interesting reverse mergers.
MAVT(.013)...increased my position.....
MAVT(.01)...possible Firetainment reverse merger.....
Finished adding to my MAVT shell position yesterday (currently have a cost basis around .007). Risk level is high due to the filing delinquency and any lingering negative market reaction to the upcoming 1:25 reverse split, but the risk/reward around this sub-penny to one-cent area continues to look pretty interesting to me.
I do have some concerns regarding exactly what happens to the $400+K debt that MAVT may still have on its books. The April 8-K regarding the proposed reverse merger with Firetainment did not specifically address this. I'm not sure if there will be any debt forgiveness, shares issued (either pre- or post-split) for the debt, or if Firetainment plans to absorb and pay off any remaining debt obligations.
But based on the disclosed terms of this RM, I think there might be some decent money to be made here. If I am interpreting the agreement correctly, the share structure could be relatively attractive (probably under 10M shares outstanding, with legacy shareholders retaining roughly 13% of the company). If in fact that is how the merger plays out, then a post-split price of 25-cents per share and an accompanying low market cap would seem to be particularly attractive.
According to an April 2017 article, Firetainment had a sales goal of $7 million for fiscal 2017, up from $2.5M in the previous year. Some excerpts from that article......
SEC's suspension policy does a disservice to investors.....
nvidiaforgames...GPLS.....
GPLS(.016)....possible website clock countdown.....
Picked up a few more shares of GPLS today. The sub-.02 shares look pretty interesting to me.
I'm a little bit puzzled/concerned about what exactly new CEO Marcus Laun is doing following the apparent reverse merger with his Growth Circle company. If in fact the RM is with Growth Circle (an IR/Media/Marketing company that provides services to a diversified list of clients/stocks), I'm not sure why the CEO has chosen to change the name of the company to Cannco Brands (a name that would suggest more of a focus on one specific industry -- marijuana-related companies). Not sure if he intends to completely shift the focus of the company to just MJ companies, or continue to service all companies.
But Marcus Laun is supposed to be a branding expert, so hopefully this move turns out well.
I'm not sure if the website link below is in fact associated with GPLS, but if it is I'm a little surprised that more Investors Hub traders and momentum groups haven't shown increasing interest lately in GPLS. Normally these website countdown clocks attract some trading interest. This website is scheduled to go active at the beginning of 2018.....
http://www.canncobrands.com/
IBGH(.004)...accumulated a position.....
I accumulated a position in the IBGH shell. Certainly a high-risk investment but the risk/reward around the .005 or lower levels looks reasonably interesting to me.
Attorney Angela Collette took control of the shell in August, and my guess is that some type of merger/acquisition activity will probably take place in this coming year. Some of the recent changes to the OTC profile (address, phone number, website, etc) over the last few weeks are somewhat confusing/concerning.
I'm not sure if the original change that highly suggested that IBGH would be doing a RM with Nutripy was simply an error or a premature release of information. But if there is a potential RM with Nutripy in the works, I think it would be a somewhat interesting company. Nutripy CEO Jeffrey Moore did a small equity-based crowd funding back in July of this year......
https://www.google.com/url?url=https://d19j0qt0x55bap.cloudfront.net/production/startups/nutripy/documents/offering_details/nutripy_offering_details__1_.pdf&rct=j&frm=1&q=&esrc=s&sa=U&ved=0ahUKEwjbn8aRkP_XAhVD7yYKHc_nCLM4ChAWCDwwCA&usg=AOvVaw0uNqjice6lluZBmBKCG3sD
There is also some possibility that Collette is preparing IBGH to be another shell for one of the client companies of William Alessi (connected to the LDSR shell). Perhaps that would lead to some type of cryptocurrency speculation. Certainly from a structural/valuation perspective, the IBGH shell would appear to be quite attractive compared to the multi-million dollar market cap of the LDSR shell.
tjvs/netmoney1999...BLLZ.....